| Document |
Document Title |
|
WO/2024/083185A1 |
The application relates to an isolated monoclonal antibody that specifically binds FGFR2B, or an antigen binding portion thereof. The application also relates to a nucleic acid molecule encoding the antibody or antigen binding portion th...
|
|
WO/2024/086792A2 |
Methods to improve homing and engraftment of hematopoietic stem cells, particularly cord blood CD34+ cells, for use in hematopoietic cell transplantation through the regulation of expression of YTHDF2 or FTO in CD34+ cells. The methods i...
|
|
WO/2024/085686A1 |
The present invention relates to: a recombinant protein comprising a foot-and-mouth disease virus (FMDV) virus-like particle (VLP) and the fragment crystallizable (Fc) region of a porcine-derived immunoglobulin linked to the surface of t...
|
|
WO/2024/082056A1 |
Described herein are antibody constructs that bind human NaPi2b (or SLC34A2) and antibody-drug conjugates (ADCs) comprising an anti-NaPi2b antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use...
|
|
WO/2024/084518A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a, 100b) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop str...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/086756A1 |
A method of treating, ameliorating, or preventing a condition characterized by one or both of reduced renal function and renal fibrosis is described, which includes interfering with one or both of an expression and an activity of a cadhe...
|
|
WO/2024/084197A1 |
The invention relates to methods for reducing the level of xenobiotic in an environment by contacting the environment with a composition comprising one or more bacterial strains. The invention also relates to bacterial strains for use in...
|
|
WO/2024/083986A1 |
The present invention relates to new peptides (cPEPs), a method for their preparation, and their use for modulating the accumulation of specific proteins.
|
|
WO/2024/086595A2 |
Systems and methods to simplify ex vivo gene therapy are described. The systems and methods provide ex vivo manufacturing of cells using target-cell enriching magnetic beads, vector-magnetic bead complexes, and a magnetic field. The pres...
|
|
WO/2024/086591A2 |
Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.
|
|
WO/2024/083958A1 |
The present invention relates to chimeric polypeptides comprising a scaffold polypeptide and one or more exogenous polypeptides, wherein the scaffold polypeptide comprises a backbone protein 2a (BP-2a) Domain 3 (D3) polypeptide in which ...
|
|
WO/2024/086661A2 |
The disclosure relates generally to gene editing systems comprising reverse transcriptases and fusion proteins of reverse transcriptases with nickases or nucleases, methods of making such reverse transcriptases and fusion proteins, and m...
|
|
WO/2024/082728A1 |
Provided are an RSB11 superior allelic variant RSB11-R and an application thereof in improving rice sheath blight resistance. Also provided is a DNA molecule (an RSB11 superior allelic variant RSB11-R promoter), the nucleotide sequence t...
|
|
WO/2024/085539A1 |
The present invention relates to a vector that operates in strains of the Bacteroides genus, which are beneficial gut microbes. The vector carries the nucleic acid sequence of SEQ ID NO: 1 necessary for the transformation of Escherichia ...
|
|
WO/2024/086514A1 |
Disclosed are methods of creating embryonic stem cells through nuclear transfer or embryo complementation. In general, methods of complementation include contacting embryonic stem cells with a host embryo. Host embryos can be wild-type e...
|
|
WO/2024/077531A1 |
The present invention relates to gene segregation and plant improvement, and in particular, to an anti-spotted wilt gene RTSW from tobacco and a use thereof. Provided are a nucleic acid molecule for conferring or enhancing the resistance...
|
|
WO/2024/080451A1 |
The present invention relates to a method for preparing a high purity DNA fragment mixture using isopropanol and magnesium chloride, wherein impurities such as moisture, blood, and fat are effectively removed and the purity of the DNA fr...
|
|
WO/2024/081167A1 |
The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucl...
|
|
WO/2024/079221A1 |
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...
|
|
WO/2024/081746A2 |
The present invention relates to nucleic acid expression cassettes that are engineered to enhance gene expression. Vectors and methods employing the expression cassettes containing novel chimeric regulatory elements are provided. The inv...
|
|
WO/2024/078485A1 |
The present invention belongs to the technical field of tumor immunotherapy, and specifically relates to a signal receptor used for targeting a tumor microenvironment and a cell for targeted treatment of tumors. The signal receptor compr...
|
|
WO/2024/080509A1 |
The present invention relates to an IGF-1 receptor-binding aptamer and a use thereof. The aptamer according to the present invention can function as a biased agonist selectively inducing only the metabolic function of the IGF-1 receptor ...
|
|
WO/2024/079662A1 |
Provided herein are improved expression constructs for the expression of UPF1 and vectors comprising such constructs. Also provided are methods of treating neurogenerative diseases, including, but not limited to, amyotrophic lateral scle...
|
|
WO/2024/081604A1 |
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...
|
|
WO/2024/078614A1 |
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and...
|
|
WO/2024/078643A1 |
Provided in the present invention are a genetically modified mouse cell, a mouse having a humanized immune system containing said mouse cell, and a construction method for the humanized mouse. The method comprises: inactivating a GFI1 ge...
|
|
WO/2024/081511A2 |
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucle...
|
|
WO/2024/078038A1 |
Provided in the present invention are a wheat leaf rust resistance protein, and an encoding gene and the use thereof The wheat leaf rust resistant protein comprises any one of the following (a)-(c): (a) a protein, which consists of the a...
|
|
WO/2024/080867A1 |
This invention relates to a method of measuring gene promotor activity and a training data set consisting of promoter activity measurements for each of a plurality of DNA fragments. The invention also relates to a computer-implemented me...
|
|
WO/2024/077478A1 |
The present invention relates to a method for preparing extracellular vesicles having reduced non-specific binding/endocytosis. By means of performing knocking out and deglycosylating operations on extracellular vesicle-related adhesion ...
|
|
WO/2024/081884A1 |
The present disclosure provides methods and compositions for the treatment of glycogen storage diseases (e.g., GSD IX). In some aspects, the present disclosure provides splice-switching oligonucleotides that correct splicing defects and ...
|
|
WO/2024/081847A1 |
An apparatus is described for concentrating biomolecules in solution, such as oligonucleotide-containing solutions, via tangential flow filtration (TFF), where the apparatus can concentrate the oligonucleotides to a concentration > 100 m...
|
|
WO/2024/081163A1 |
Provided herein are methods of treating leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) in a subject in need thereof, the method comprising: administering a therapeutic agent to the subject, wh...
|
|
WO/2024/079655A1 |
The present disclosure provides methods for producing and purifying recombinant adeno associated virus (AAV) vectors, including separating of full capsids from empty capsids, using anion exchange chromatography in weak partitioning mode....
|
|
WO/2024/079460A1 |
The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions ...
|
|
WO/2024/079109A1 |
The invention relates to a genetically modified natural killer (NK) cell, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular antigen-binding domain that specifically...
|
|
WO/2024/080311A1 |
[Problem] The present invention addresses the following to-be-solved problems: there are no gene introduction methods that have a high gene introduction efficiency and high specificity for skin, subcutaneous tissues, skin ulcer surfaces,...
|
|
WO/2024/081411A1 |
Described herein are recombinant polynucleotides encoding small RNA payloads, such as engineered guide RNAs. The small RNA payloads may include stability elements to increase stability of the small RNA payload encoded by the recombinant ...
|
|
WO/2024/079110A1 |
The invention relates to a nucleic acid construct for targeting and integrating a binding domain in- frame into an endogenous CD3 epsilon gene of a human cell. The invention further relates to a genetically modified human T cell comprisi...
|
|
WO/2024/081596A1 |
Provided herein is a method that involves lysing cells that have a fusion between a first gene and a second gene at an end of an electrophoresis gel, applying a voltage potential to the gel to intact genomic DNA at one end of the gel, di...
|
|
WO/2024/079137A1 |
There is disclosed a mutant, non-naturally occurring or transgenic plant or part of the plant having reduced or inhibited expression or activity of NtNTP2-T or reduced or inhibited expression or activity of NtNTP2-T and NtNTP2-S, said Nt...
|
|
WO/2024/078558A1 |
An anti-CD100 antibody and a use thereof, a pharmaceutical composition or pharmaceutical combination comprising the antibody, and a use thereof. Further provided are a polynucleotide encoding the antibody, an expression vector, and a met...
|
|
WO/2024/077815A1 |
Provided are an adeno-associated virus capsid protein mutant having an unactivated T cell targeting property and the use thereof. The mutant comprises a sequence as shown in any one of SEQ ID Nos. 9-12. The recombinant adeno-associated v...
|
|
WO/2024/081820A1 |
Provided herein are targeted lipid particles, such as targeted lentiviral particles, having a targeting agent that binds to a target molecule selected from the group consisting of ASCT1, ASCT2, CD105, CD110, CD117, CD133, CD146, CD164, C...
|
|
WO/2024/080304A1 |
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell su...
|
|
WO/2024/079358A1 |
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the...
|
|
WO/2024/078570A1 |
It relates to immune cells (e.g., T cells such as CAR-T cells, NK cells such as CAR-NK cells) modified to have no or reduced expression and/or function of one or more target proteins selected from the group consisting of: Signal Peptide ...
|
|
WO/2024/077547A1 |
The present invention relates to a B7H3/PDL1 bispecific antibody, and a pharmaceutical composition comprising same and a use thereof. The bispecific antibody can bind to B7H3 and PDL1 in a targeted manner, and comprises: a monoclonal ant...
|
